By Fineline Cube 
China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for SM2275, a dual-target nanobody-based anti-tumor therapy. This approval marks a significant milestone in the development of innovative cancer treatments.
Mechanism of Action
SM2275 distinguishes itself through a “dual-target + conditional co-stimulation” mechanism. It simultaneously blocks the EGFR pathway and the PD-L1 immune checkpoint, while selectively activating CD28 signaling to enhance the tumor-killing capacity of T cells within the tumor microenvironment. This multi-faceted approach offers a novel strategy for cancer treatment.
Preclinical Results
Preclinical studies have demonstrated SM2275’s broad anti-tumor potential, highlighting its ability to address a variety of cancers. The drug’s unique mechanism of action positions it as a promising candidate in the evolving landscape of oncology therapies.-Fineline Info & Tech